March 16th 2023
National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.
February 25th 2023
January 25th 2023
FDA Allows Marketing of Tissue Containment System for Use in Power MorcellationApril 8th 2016
While continuing to warn against use of laparoscopic power morcellators for the removal of uterus or uterine fibroids in most women, the FDA is allowing the marketing of a containment system for use with certain power morcellators to isolate tissue not suspected to be cancerous.
Analysis Validates Use of PFS As Surrogate Endpoint in Sarcoma TrialsMarch 8th 2016
An analysis of randomized controlled trials in soft-tissue sarcoma over 40 years found that progression-free survival and response rate are reasonably well correlated with overall survival, and are thus acceptable surrogates to use.
Prognostic Nomogram for Retroperitoneal Sarcoma Validated in Large CohortMarch 3rd 2016
A new study validated a prognostic nomogram for retroperitoneal sarcoma using a large, external cohort. The nomogram incorporates six variables, and provided strong concordance with observed disease-free and overall survival.
Neoadjuvant Therapy for Soft-Tissue Sarcomas-One Size Does Not Fit AllJanuary 15th 2016
Improvements in neoadjuvant therapy for soft-tissue sarcomas will require the development of more efficacious systemic therapies and, if possible, the performance of histology-specific, prospective, randomized clinical trials to advance the field.
Multi-Agent, Dose-Intensive Regimen Improves EFS in RhabdomyosarcomaOctober 30th 2015
A treatment strategy including dose intensification with interval compression, use of the most active agents available, and the use of irinotecan as a radiation sensitizer led to a promising event-free survival rate in certain patients with metastatic rhabdomyosarcoma.
ASCO 2015: Sarcoma Poster Presentations & DiscussionsJune 29th 2015
Sarcomas are a heterogeneous and motley collection of cancers, which struggle with an identity crisis on many levels. The trials often lump vastly different subgroups, and are often unable to collect sufficient numbers of any one disease subtype to complete a unique cohort.
Investigational Treatment & Imaging Frequency Help Predict Sarcoma OutcomeJune 25th 2015
Advanced imaging techniques could allow clinicians the ability to determine as early as 9 days into sarcoma treatment whether the therapy will be effective in a given patient, according to a new University of Michigan study.